Susquehanna International Group, LLP Biomea Fusion, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$4.23 - $10.1 $167,931 - $400,970	39,700 Added 29.76%	173,100 $1.75 Million
Q2 2024 Aug 15, 2024	SELL	$4.14 - $15.3 $1.9 Million - $7.02 Million	-458,600 Reduced 77.47%	133,400 $600,000
Q1 2024 May 07, 2024	BUY	$13.92 - $19.5 $1.81 Million - $2.54 Million	130,200 Added 28.19%	592,000 $8.85 Million
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $3.64 Million - $8.61 Million	435,100 Added 1629.59%	461,800 $6.71 Million
Q3 2023 Nov 14, 2023	SELL	$13.44 - $23.02 $1.39 Million - $2.38 Million	-103,400 Reduced 79.48%	26,700 $367,000
Q2 2023 Aug 11, 2023	BUY	$21.66 - $41.8 $1.95 Million - $3.76 Million	90,000 Added 224.44%	130,100 $2.86 Million
Q1 2023 May 16, 2023	BUY	$6.8 - $32.35 $272,680 - $1.3 Million	40,100 New	40,100 $1.24 Million

105

17.9M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $191M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.